The COVID pandemic ushered mRNA vaccines into the spotlight, and the technology has even greater potential. Here’s what to ...

Once considered cellular junk, non-coding RNAs are emerging as key players in everything from brain development to cancer — ...

When people talk about transformative technologies today, the conversation usually moves quickly to artificial intelligence, ...

Existing bacteria and archaea still our universal common ancestor’s ribosomal hibernation defense mechanism when nutrients ...

Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...

Sarepta stock popped Wednesday after the company reported promising results for its gene-silencing tech in two forms of muscular dystrophy.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination ...

CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payn ...

A research team from The Hong Kong University of Science and Technology (HKUST) has made an advance in understanding the molecular machinery of RNA silencing. The team uncovered how the human enzyme ...